Durability of FIT Screening After Cessation of a Screening Outreach Intervention.
Cancer prevention
Colorectal cancer screening
Durability of CRC screening
FIT testing for colorectal cancer screening
Randomized Control Trial
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
27
07
2022
accepted:
26
10
2022
medline:
28
4
2023
pubmed:
11
11
2022
entrez:
10
11
2022
Statut:
ppublish
Résumé
Organized outreach to increase CRC screening using mailed FIT tests has been shown to be effective, but durable changes to screening behavior after cessation of screening is not known. In this study, after cessation of funding for an organized cancer screening outreach program, we evaluated whether adherence to screening remained elevated. Patients aged 50-75 years eligible for CRC screening from eight safety net clinics were randomly assigned to outreach intervention vs usual care alone in 2016 to 2018; the primary outcome analyzed was the difference in the cumulative proportion of completed FIT screening between study assignments 1 year after study cessation. Despite higher rates of FIT screening for patients who were randomly assigned to the outreach intervention, FIT completion was not significantly different between the group that received the outreach services versus the usual care group (28.3% vs 29.8%, p = 0.158). Outreach campaigns and their activities must be sustained to maintain improved rates of screening participation.
Identifiants
pubmed: 36357595
doi: 10.1007/s10620-022-07755-7
pii: 10.1007/s10620-022-07755-7
pmc: PMC9648881
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1777-1779Informations de copyright
© 2022. The Author(s).
Références
Siegel RL, Miller KD, Sauer AG et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145–164.
doi: 10.3322/caac.21601
pubmed: 32133645
US Preventive Services Task Force, Davidson KW, Barry MJ et al. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325:1965–1977.
doi: 10.1001/jama.2021.6238
Bretthauer M, Løberg M, Wieszczy P et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med. 2022;387:1547–1556.
doi: 10.1056/NEJMoa2208375
pubmed: 36214590
Issaka RB, Avila P, Whitaker E, Bent S, Somsouk M. Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: a systematic review. Prev Med. 2019;118:113–121.
doi: 10.1016/j.ypmed.2018.10.021
pubmed: 30367972
Somsouk M, Rachocki C, Mannalithara A et al. Effectiveness and cost of organized outreach for colorectal cancer screening: a randomized, controlled trial. J Natl Cancer Inst. 2019;112:305–313.
doi: 10.1093/jnci/djz110
pmcid: 7017601
Heidemann DL, Adhami A, Nair A et al. Using a frontline staff intervention to improve cervical cancer screening in a large academic internal medicine clinic. J Gen Intern Med. 2021;36:2608–2614.
doi: 10.1007/s11606-021-06865-8
pubmed: 33987788
pmcid: 8390589
Patel SY, Mehrotra A, Huskamp HA, Uscher-Pines L, Ganguli I, Barnett ML. Trends in outpatient care delivery and telemedicine during the COVID-19 pandemic in the US. JAMA Intern Med. 2021;181:388–391.
doi: 10.1001/jamainternmed.2020.5928
pubmed: 33196765
Balzora S, Issaka RB, Anyane-Yeboa A, Gray DM II, May FP. Impact of COVID-19 on colorectal cancer disparities and the way forward. Gastrointest Endosc 2020;92:946–950.
doi: 10.1016/j.gie.2020.06.042
pubmed: 32574570
pmcid: 7529970
Patel S, Issaka RB, Chen E, Somsouk M. Colorectal cancer screening and COVID-19. Am J Gastroenterol. 2021;116:433–434.
doi: 10.14309/ajg.0000000000000970
pubmed: 33038127
Gupta S, Coronado GD, Argenbright K et al. Mailed fecal immunochemical test outreach for colorectal cancer screening: summary of a Centers for Disease Control and Prevention-sponsored Summit. CA Cancer J Clin 2020;70:283–298.
doi: 10.3322/caac.21615
pubmed: 32583884
pmcid: 7523556